Summary of Key Findings
In February 2026, a paper published in *Nature Medicine* claimed that patients with advanced lung cancer who received PD-1 immunotherapy combined with chemotherapy before 3 p.m. had twice the survival rate (both progression-free survival and overall survival) compared to those treated after 3 p.m. This finding, which seemingly offered a way to enhance treatment efficacy for no additional cost, instantly sparked a global medical sensation. However, just 17 days later, the journal issued a warning about the paper, and it was officially retracted four months later. The reasons for the withdrawal were numerous serious issues: no patients discontinued the trial due to side effects (which is almost impossible in cancer studies), an abnormally smooth survival curve, frequent changes to the trial design, and the use of references from papers published after the study’s completion. Although there is a theoretical basis for the idea that the biological clock may affect the effectiveness of immunotherapy, this unique prospective randomized controlled trial (the highest level of evidence) was dismissed due to its unreliable data, prompting reflection on academic peer review processes and clinical trial standards.
Why Did This Paper Suddenly Become So Popular?
The paper’s popularity was largely due to two factors:
1. Amazing Results at No Cost: Using the same medication but changing the timing of the injection increased patients’ overall survival by nearly a year (from 16.8 months to 28 months). Such a significant improvement without any additional investment in new drugs was particularly appealing.
2. Scientific Support: The findings were backed by research in the field of circadian immunology, which has shown that immune cell activity follows a daily rhythm with stronger inflammatory responses during the day. Previous retrospective studies had suggested that morning treatments might be more effective, but this was the first time such claims were verified using a randomized controlled trial, the most rigorous method in medicine. Even renowned medical experts recommended the study, and investors joked about it, indicating its widespread attention.
Issues That Revealed the Paper’s Flaws
Within days of its publication, several flaws were identified by researchers and doctors:
- No Patients Discontinued the Trial? Side effects of immunotherapy (such as rashes, hepatitis, and pneumonia) are common, so it’s unlikely that no patient would stop the treatment. For example, in a similar trial conducted by Kangfang Biosciences, 4.5% of patients discontinued the trial due to side effects; based on this rate, at least 9 out of 210 participants should have dropped out, yet in this paper, none did—this seemed too perfect to be true.
- Abnormally Smooth Survival Curve: In typical trials, tumor progression is more evident on the day of imaging examinations, resulting in a stepped decline in survival curves. The authors attributed the smooth curve to disruptions caused by COVID-19, but the journal deemed this a violation of trial protocol, questioning the reliability of the data.
- Frequent Changes to the Trial Design: Registration records showed that the type of trial (interventional vs. observational), outcome criteria, and inclusion criteria were repeatedly altered. While these changes might not have been illegal, they could have introduced bias, such as selecting patients more suitable for morning treatments.
- References from Later Papers: The trial protocol was dated January 2022 but cited papers published between 2022 and 2024, suggesting that the authors used information from later studies during the trial’s conduct.
The Withdrawal Did Not Disprove the Biological Clock Theory
The withdrawal of the paper did not deny the potential impact of the biological clock on immunotherapy; rather, it questioned the reliability of the specific experimental design. For instance, a retrospective study in *Blood* in March 2026 found that lymphoma patients receiving CAR-T cell therapy in the morning had a higher one-year progression-free survival rate, and similar trends were observed in kidney cancer studies. However, these are retrospective studies that can be influenced by confounding factors (e.g., patients seen in the morning may be wealthier and healthier). As the only prospective randomized controlled trial, this paper’s findings were of the highest credibility, but they proved to be unreliable.
Lessons Learned from This Incident
This incident highlights two critical issues:
1. Weak Peer Review: The paper’s flaws were evident shortly after publication, yet it was approved by *Nature Medicine.* Possible reasons include reviewers not receiving adequate compensation and the high volume of submissions, leaving them with limited time to conduct thorough reviews. Doctor Tarrantino called for stricter peer review processes for studies that impact patient treatment.
2. Randomization Must Be Accurate: Randomization should be done before treatment; in this case, it was performed on the same day as the treatment, allowing doctors to potentially assign patients to groups based on their conditions, which could bias the results. Compliance with trial protocols is essential for the validity of data.
Implications for Patients and Doctors
- Patients Should Not Change Treatment Times Arbitrarily: Before the paper was retracted, some patients asked if they could switch to morning treatments, but given the unreliable findings, changing the timing may have delayed their recovery.
- Doctors Need More Solid Evidence: Clinical practices should not be altered based on a single study; more reliable trials are needed to confirm the effects of treatment times. For example, European studies analyzing data from over 3,000 patients found little impact of treatment time on outcomes, and similar findings were observed in breast cancer research.
- Science Should Proceed with Caution: While rapid results can be tempting, they may not always be reliable. The astonishing findings of this paper should serve as a cautionary tale—too good to be true often indicates potential issues.
Conclusion
This incident marks the beginning of further investigation into the role of circadian rhythms in immunotherapy, which requires more rigorous and well-designed studies. Scientific progress relies on solid data, not just sensational papers. For patients, it’s crucial to trust medical professionals and avoid relying on unproven “miracle” treatments, as life cannot afford mistakes.